T. Pielak

Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.

Michael C. McDaniel, A. Quyyumi, B. Gogas, 2015, Atherosclerosis.

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

C. Höybye, J. Eugen-Olsen, T. Pielak, 2019, Endocrine connections.

Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

E. B. Petersen, J. Eugen-Olsen, T. Pielak, 2020, Scandinavian journal of clinical and laboratory investigation.

Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death

A. Quyyumi, V. Vaccarino, S. Epstein, 2017, Circulation. Cardiovascular quality and outcomes.

Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events

A. Quyyumi, D. Kremastinos, N. Le, 2014, Journal of the American Heart Association.

Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population

T. Hansen, J. Jeppesen, K. Borch-Johnsen, 2010, Journal of internal medicine.

Smoking Has No Influence on Outcomes after Repair of the Medial Meniscus in the Hypo and Avascular Zones—A Pilot Study

J. Kruczyński, Ł. Łapaj, J. Zabrzyński, 2022, International journal of environmental research and public health.

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial

T. Hansen, P. Rossing, F. Persson, 2017, Diabetes, obesity & metabolism.